Drug Profile
Research programme: anti-CA9 vaccine - Dendreon
Latest Information Update: 28 Apr 2014
Price :
$50
*
At a glance
- Originator Dendreon Corporation
- Class Cancer vaccines
- Mechanism of Action Carbonic anhydrase inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 31 Dec 2013 Suspended - Preclinical for Cancer in USA (Parenteral)
- 31 Dec 2011 Anti-CA9 vaccine is still in preclinical development for Cancer in USA
- 28 Sep 2009 Preclinical development is ongoing in USA